GH-RH antagonist (MZ-4-71) inhibits VEGF secretion and proliferation of murine endothelial cells

Life Sciences

Volumn 72, Issue 22, 2003, Pages 2473-2479

  Siejka, A ^a   Lawnicka H ^a   Komorowski, J ^a   Schally, A V ^b   Stepien T ^a   Krupinski R ^a   Stepien H ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; GH RH analogs; Proliferation; VEGF

Indexed keywords

GROWTH HORMONE DERIVATIVE; GROWTH HORMONE RELEASING FACTOR; GROWTH HORMONE RELEASING FACTOR ANTAGONIST; GROWTH HORMONE RELEASING FACTOR DERIVATIVE; MITOGENIC AGENT; MZ 4 71; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CARCINOGENESIS; CELL PROLIFERATION; CELL SPECIFICITY; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; ENDOTHELIUM CELL; IN VITRO STUDY; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; SOLID TUMOR;

MURINAE;

EID: 0037453207     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(03)00164-4     Document Type: Article

References (38)

1. Akeno N., Robins J., Zhang M., Czyzyk-Krzeska M.F., Clemens T.L. Induction of vascular endothelial growth factor by IGF-I in osteoblast-like cells is mediated by the PI3K signaling pathway through the hypoxia-inducible factor-2α Endocrinology. 143:2002;420-425.
2. Benlot C., Lévy L., Fontanaud P., Roche A., Rouannet P., Joubert D. Somatostatin and growth hormone-releasing hormone in normal and tumoral human breast tissue: endogenous content, in vitro pulsatile release, and regulation. Journal of Clinical Endocrinology and Metabolism. 82:1997;690-696.
3. Berry S.A., Srivastava C.H., Rubin L.R., Phipps W.R., Pescovitz O.H. Growth hormone-releasing hormone-like messenger ribonucleic acid and immunoreactive peptide are present in human testis and placenta. Journal of Clinical Endocrinology and Metabolism. 75:1992;281-284.
4. Bizouarne N., Denis V., Legrand A., Monsigny M., Kieda C. A SV-40 immortalized murine endothelial cell line from peripheral lymph node high endothelium expresses a new alpha-L-fucose binding protein. Biology of the Cell. 79:1993;209-218.
5. Brown L.F., Berse B., Jackman R.W., Tognazzi K., Manseau E.J., Dvorak H.F., Senger D.R. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. American Journal of Pathology. 143:1993;1255-1262.
6. Bussolino F., Albini A., Camussi G., Presta M., Viglietto G., Ziche M. Role of soluble mediators in angiogenesis. European Journal of Cancer. 14:1996;2401-2412.
7. Carmeliet P., Dor Y., Herbert J.M., Fukumura D., Brusselmans K., Dewerchin M. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature. 394:1998;485-490.
8. Chan J.M., Stampfer M.J., Giovannucci E., Gann P.H., Ma J., Wilkinson P., Hennekens C.H., Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science. 279:1998;563-566.
9. Chatzistamou I., Schally A.V., Varga J.L., Groot K., Busto R., Armatis P., Halmos G. Inhibition of growth and metastases of MDA-MB-435 human estrogen-independent breast cancers by an antagonist of growth hormone-releasing hormone. Anticancer Drugs. 12:2001;761-768.
10. Christofides N.D., Stephanou A., Suzuki H., Yiangou Y., Bloom S.R. Distribution of immunoreactive growth hormone-releasing hormone in the human brain and intestine and its production by tumours. Journal of Clinical Endocrinology and Metabolism. 59:1984;747-751.
11. Dirix L.Y., Vermeulen P.B., Pawiński A., Prove A., Benoy I., De Pooter C., Martin M., Van Oosterom A.T. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. British Journal of Cancer. 76:1997;238-243.
12. Ferrara N. Vascular endothelial growth factor. European Journal of Cancer. 32A:1996;2413-2422.
13. Folkman J. Tumor angiogenesis: therapeutic implications. New England Journal of Medicine. 285:1971;1182-1186.
14. Guillemin R., Brazeau P., Böhlen P., Esch F., Ling N., Wehrenberg W.B. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science. 218:1982;585-587.
15. Halmos G., Schally A.V., Varga J.L., Plonowski A., Rekasi Z., Czompoly T. Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone. Proceedings of the National Academy of Sciences USA. 97:2000;10555-10560.
16. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:1996;353-364.
17. Hankinson S.E., Willet W.C., Colditz G.A., Hunter D.J., Michaud D.S., Deroo B., Rosner B., Speizer F.E., Pollak M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet. 351:1998;1393-1396.
18. Kahán Z., Arencibia J.M., Csernus V.J., Groot K., Kineman R.D., Robinson W.R., Schally A.V. Expression of growth hormone-releasing hormone (GHRH) messenger ribonucleic acid and the presence of biologically active GHRH in human breast, endometrial, and ovarian cancers. Journal of Clinical Endocrinology and Metabolism. 84:1999;582-589.
19. Karayiannakis A.J., Syrigos K.N., Zbar A., Baibas N., Polychronidis A., Simopoulos C., Karatzas G. Clinical significance of preoperative serum vascular endothelial growth factor levels in patients with colorectal cancer and the effect of tumor surgery. Surgery. 131:2002;548-555.
20. Keck P.J., Hauser S.D., Krivi G., Sanzo K., Warren T., Feder J., Connolly D.T. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 246:1989;1309-1312.
21. Kiaris H., Schally A.V., Busto R., Halmos G., Artavanis T.S., Varga J.L. Expression of a splice variant of the receptor for GHRH in 3T3 fibroblasts activates cell proliferation responses to GHRH analogs. Proceedings of the National Academy of Sciences USA. 99:2002;196-200.
22. Kineman R.D. Antitumorigenic actions of growth hormone-releasing hormone antagonists. Proceedings of the National Academy of Sciences USA. 97:2000;532-534.
23. Liekens S., de Clerq E., Neyts J. Angiogenesis: regulators and clinical applications. Biochemical Pharmacology. 61:2001;253-270.
24. Ławnicka H., Stȩpień H., Wyczółkowska J., Kolago B., Kunert-Radek J., Komorowski J. Effect of somatostatin and octreotide on proliferation and vascular endothelial growth hormone secretion from murine endothelial cell line (HECa10) culture. Biochemical an Biophysical Research Communications. 268:2000;567-571.
25. Mayo K.E., Godfrey P.A., Suhr S.T., Kulik D.J., Rahal J.O. Growth hormone-releasing hormone: synthesis and signaling. Recent Progress in Hormonal Research. 50:1995;35-73.
26. Okada F., Rak J.W., Croix B.S., Lieubeau B., Kaya M., Roncari L., Shirasawa S., Sasazuki T., Kerbel R.S. Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proceedings of the National Academy of Sciences USA. 95:1998;3609-3614.
27. Plonowski A., Schally A.V., Krupa A., Hebert F., Groot K., Varga J.L. The inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone is not correlated with the suppression of serum IGF-I or tumoral IGF-II and vascular endothelial growth factor. Prostate. 52:2002;173-182.
28. Punglia R.S., Lu M., Hsu J., Kuroki M., Tolentino M.J., Keough K., Levy A.P., Levy N.S., Goldberg M.A., D'Amato R.J., Adamis A.P. Regulation of vascular endothelial growth factor expression by insulin-like growth factor I. Diabetes. 46:1997;1619-1626.
29. Rak J.W., St. Croix B.D., Kerbel R.S. Consequences of angiogenesis for tumor progression, metastasis, and cancer therapy. Anticancer Drugs. 6:1995;3-18.
30. Rekasi Z., Czompoly T., Schally A.V., Halmos G. Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers. Proceedings of the National Academy of Sciences USA. 97:2000;10561-10566.
31. Rivier J., Spiess J., Thorner M., Vale W. Characterisation of a growth hormone-releasing factor from a human pancreatic islet tumour. Nature. 300:1982;276-278.
32. 2 as a GRF antagonist on membranes. Endocrinology. 117:1985;1759-1764.
33. Schally A.V., Comaru-Schally A.M., Nagy A., Kovacs M., Szepeshazi K., Plonowski A., Varga J.L., Halmos G. Hypothalamic hormones and cancer. Frontiers in Neuroendocrinology. 22:2001;248-291.
34. Stȩpień H.M., Kołomecki K., Pasieka Z., Komorowski J., Stȩpień T., Kuzdak K. Angiogenesis of endocrine gland tumours - new molecular targets in diagnostics and therapy. European Journal of Endocrinology. 146:2002;143-151.
35. Szepeshazi K., Schally A.V., Groot K., Armatis P., Hebert F., Halmos G. Antagonists of growth hormone-releasing hormone (GH-RH) inhibit in vivo proliferation of experimental pancreatic cancers and decrease IGF-II levels in tumours. European Journal of Cancer. 36:2000;128-136.
36. Warren R.S., Yuan H., Matli M.R., Ferrara N., Donner D.B. Induction of vascular endothelial growth factor by insulin-like growth factor I in colorectal carcinoma. Journal of Biological Chemistry. 271:1996;29483-29488.
37. Wu Y., Saldana L., Chillar R., Vadgama J.V. Plasma vascular endothelial growth factor is useful in assessing progression of breast cancer post surgery and during adjuvant treatment. International Journal of Oncology. 20:2002;509-516.
38. Zarandi M., Horvath J.E., Halmos G., Pinski J., Nagy A., Groot K., Rekasi Z., Schally A.V. Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone. Proceedings of the National Academy of Sciences USA. 91:1994;12298-12302.